L-DOPA exacerbates amphetamine-induced dopamine depletion

Area of Science:

• Neuroscience
• Pharmacology
• Neurotoxicology

Background:

• Parkinson's disease treatment with Levodopa (L-DOPA) may worsen nigrostriatal system denervation.
• Investigating the combined effects of L-DOPA and DOPA decarboxylase inhibitors on neurotoxicity is crucial for understanding treatment-related risks.

Purpose of the Study:

• To determine if L-DOPA, when combined with the DOPA decarboxylase inhibitor benserazide hydrochloride, potentiates amphetamine-induced neurotoxicity.
• To explore the impact of this combination on dopamine and serotonin levels in the striatum and frontal cortex.

Main Methods:

• Mice received two injections of saline or benserazide + L-DOPA (25.0 or 100.0 mg/kg).
• Four injections of amphetamine (15.0 mg/kg) were administered at 2-hour intervals.
• Striatal dopamine, DOPAC, HVA, and 5-HT levels, as well as 5-HT turnover, were measured one week post-treatment.

Main Results:

• Amphetamine administration with or without 25.0 mg/kg L-DOPA + benserazide significantly depleted striatal dopamine, DOPAC, and HVA.
• 100.0 mg/kg L-DOPA + benserazide potentiated amphetamine-induced striatal dopamine depletion (17% vs 28% of control values), linked to increased dopamine turnover (360% vs 231%).
• Concurrent L-DOPA/benserazide administration depleted striatal 5-HT (to 82% of control), while L-DOPA/benserazide alone reduced 5-HT and its turnover in the frontal cortex (to 58% of control).

Conclusions:

• Combined administration of L-DOPA and benserazide hydrochloride potentiates amphetamine-induced striatal dopamine depletion in mice.
• This potentiation may result from increased dopamine turnover, mimicking compromised dopaminergic systems in Parkinson's patients.
• The combination affects serotonin levels, highlighting potential broader neurochemical impacts beyond dopamine.